Page 165 - pharma 1 theoretical updated MNU_Neat
P. 165

Clinical pharmacy 2024/2025                            Level 3 Pharm D                             Pharmacology 1 (PO 502)
                                    1- Unfractionated Heparin (UFH)



                        Heparin (heparinic acid or unfractionated heparin (UFH)) is a strongly
             It’s
                          acidic, high molecular weight mucopolysaccharide. (up to 40,000 Da)

                       ➢  indirectly inactivates thrombin and factor Xa by activating antithrombin
                         1)  The inhibitory enzyme antithrombin through Penta saccharides

                              sequences works by forming a 1:1 complex with both thrombin (Factor
                              IIa) and factor Xa.
           MOA           2)  The rates of these reactions are slow in absence of heparin, binding is

                              accelerated 1000-fold in presence of heparin.
                         3)  Heparin binds to and activate antithrombin → accelerates its binding
                              to thrombin and factor Xa → inactivation of thrombin, factor Xa and

                              other proteases → decrease blood clotting
                               bleeding, thrombocytopenia (HIT), osteoporosis and elevation of
             S/E
                                                           transaminases

           routes                                 IV, followed by IV infusion.
         Reversal:             Discontinue heparin (short half-life) and/or Protamine Sulfate

















                                           Heparinoid (Danaparoid)




          licensed for  prophylaxis of DVT in patients undergoing general or orthopedic surgery.


                           ➢  a mixture of the low molecular weight sulphated glycosamino-

               It is           glycuronans: heparin sulphate, dermatan sulphate and a small amount of
                               chondroitin sulphate


                           ➢  IV in the treatment of individuals who develop HIT but still need
               used
                               ongoing anticoagulation.





                                                                                                     | P a g e  149
   160   161   162   163   164   165   166   167   168   169   170